

# SmartPA Criteria Proposal

<b>Drug/Drug Class:</b>	Thiazolidinediones & Combination Agents PDL Edit
<b>First Implementation Date:</b>	January 8, 2009
<b>Revised Date:</b>	October 14, 2021
<b>Prepared For:</b>	MO HealthNet
<b>Prepared By:</b>	MO HealthNet/Conduent
<b>Criteria Status:</b>	<input type="checkbox"/> Existing Criteria <input checked="" type="checkbox"/> Revision of Existing Criteria <input type="checkbox"/> New Criteria

## Executive Summary

**Purpose:** The MO HealthNet Pharmacy Program will implement a state-specific preferred drug list.

**Why Issue Selected:** Type 2 diabetes mellitus is a significant health problem associated with excessive morbidity and mortality. As the prevalence of this metabolic disorder is rapidly increasing and as older treatments fail to stabilize the disease in many participants, prevention and control are considered key objectives. Thiazolidinediones (TZDs) improve glycemic control by improving insulin sensitivity in muscle and adipose tissue and inhibit hepatic gluconeogenesis. They depend on the presence of insulin for their mechanism of action. TZDs have known significant adverse events, such as new onset of congestive heart failure, edema, and hepatic failure. TZDs should not be used by individuals with NYHA Class III or IV heart failure as they can cause fluid retention. The 2021 American Diabetes Association Standards of Medical Care in Diabetes recognizes TZDs as possible second line agents in addition to metformin in participants who do not have cardiovascular disease or chronic kidney disease. These agents are also available in oral combination agents that include ActoplusMet® (pioglitazone/metformin) and Duetact® (pioglitazone/glimepiride).

Total program savings for the PDL classes will be regularly reviewed.

Program-Specific Information:	Preferred Agents	Non-Preferred Agents
	<ul style="list-style-type: none"> <li>• Pioglitazone</li> </ul>	<ul style="list-style-type: none"> <li>• ActoplusMet®</li> <li>• Actos®</li> <li>• Avandia®</li> <li>• Duetact®</li> <li>• Pioglitazone/Glimepiride</li> <li>• Pioglitazone/Metformin</li> </ul>

**Type of Criteria:**  Increased risk of ADE  Preferred Drug List  
 Appropriate Indications  Clinical Edit

**Data Sources:**  Only Administrative Databases  Databases + Prescriber-Supplied

## Setting & Population

- Drug class for review: Thiazolidinediones & Combination Agents
- Age range: All appropriate MO HealthNet participants

## Approval Criteria

- Failure to achieve desired therapeutic outcomes with trial on 1 or more preferred agents
  - Documented trial period of preferred agents **OR**
  - Documented ADE/ADR to preferred agents

## Denial Criteria

- Lack of adequate trial on required preferred agents
- Documented diagnosis of heart failure
- For Avandia: concurrent use of insulin **OR** nitrates in the past 30 days
- Therapy will be denied if all approval criteria are not met
- Claim exceeds maximum dosing limitation for the following:

Drug Description	Generic Equivalent	Max Dosing Limitation
ACTOPLUS MET 15MG/500MG	PIOGLITAZONE/METFORMIN	3 tablets per day
ACTOPLUS MET 15MG/850MG	PIOGLITAZONE/METFORMIN	3 tablets per day
ACTOS 15 MG	PIOGLITAZONE	1 tablet per day
ACTOS 30 MG	PIOGLITAZONE	1 tablet per day
ACTOS 45 MG	PIOGLITAZONE	1 tablet per day
AVANDIA 2 MG	ROSIGLITAZONE	2 tablets per day
AVANDIA 4 MG	ROSIGLITAZONE	2 tablets per day
<b>DUETACT 30-4 MG TABLET</b>	<b>PIOGLITAZONE/GLIMEPIRIDE</b>	<b>1 tablet per day</b>
<b>DUETACT 30-2 MG TABLET</b>	<b>PIOGLITAZONE/GLIMEPIRIDE</b>	<b>1 tablet per day</b>

## Required Documentation

Laboratory Results:   
MedWatch Form:

Progress Notes:   
Other:

## Disposition of Edit

Denial: Exception Code "0160" (Preferred Drug List)  
Rule Type: PDL

## Default Approval Period

1 year

## References

1. USPDI, Micromedex; 2021.
2. Facts and Comparisons eAnswers (online); 2021Clinical Drug Information, LLC.
3. Evidence-Based Medicine and Fiscal Analysis: "Oral Antihyperglycemics: Thiazolidinediones (TZDs) and Combination Agents – Therapeutic Class Review", Conduent Business Services, L.L.C., Richmond, VA; June 2021.

*SmartPA PDL Proposal Form*

© 2021 Conduent Business Services, LLC. All rights reserved. Conduent™ and Conduent Design™ are trademarks of Conduent Business Services, LLC in the United States and/or other countries.

Other company trademarks are also acknowledged.

4. Drug Effectiveness Review Project – Drug Class Review on Thiazolidinediones. Center for Evidence-Based Policy, Oregon Health & Science University; May 2006/Update September 2009.
5. Evidence-Based Medicine Analysis: “Thiazolidinediones”, UMKC-DIC; March 2021.
6. American Diabetes Association (ADA). Standards of Medical Care in Diabetes – 2021. *Diabetes Care*. 2021;44(suppl 1): S1-S232.
7. Avandia [package insert]. Research Triangle Park, NC: GlaxoSmithKline; November 2020.
8. Actos [package insert]. Deerfield, IL: Takeda Pharmaceuticals America Inc; June 2020.
9. American Diabetes Association (ADA). Standards of Medical Care in Diabetes-2020. *Diabetes Care*. 2020;43(suppl 1): S1-S212.